Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | May 14, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date May 14, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-05-13 | Direct | 9,149 |
Reported balance
After 2026-05-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 9,149 · Balance 9,149 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 25, 2025
Section 16 reporting ended · disclosed 2025-02-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectThe Barker/Loring Trust Dated August 27, 2013 | 0 |
Reported balance
After 2025-02-21 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-21 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2: The Reporting Person is the trustee of The Barker/Loring Trust and has voting and dispositive power with respect to these shares. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $672.90 · Expires 2031-05-05 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-21 · Disposition to issuer · Disposed 666 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $85.80 · Expires 2032-05-26 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-21 · Disposition to issuer · Disposed 1,541 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2033-05-25 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.16 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-02-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-02-21 · Disposition to issuer · Disposed 2,466 · Balance 0 F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
F2: The Reporting Person is the trustee of The Barker/Loring Trust and has voting and dispositive power with respect to these shares.
F3: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
F4: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 14, 2026 22:14 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 9,149 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001189124-26-000002 · ownership.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,149 Underlying: Common Stock · 9,149 shares Expires 2036-05-13 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 20:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 2,775 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001411690-25-000066 · wk-form4_1749761417.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 2,775 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,466 | $8.84 Strike: $11.16 | $21,799.44 |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · derivative · entry 6 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,466 shares Expires 2034-05-29 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,466 | $0.00 Strike: $31.80 | $0.00 |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · derivative · entry 5 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,466 shares Expires 2033-05-25 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,541 | $0.00 Strike: $85.80 | $0.00 |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · derivative · entry 4 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,541 shares Expires 2032-05-26 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerStock Option (Right to Buy) · Derivative | 666 | $0.00 Strike: $672.90 | $0.00 |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · derivative · entry 3 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 666 shares Expires 2031-05-05 F4 · price: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. F3 · derivative.exercise_date: As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · nonDerivative · entry 2 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The Barker/Loring Trust Dated August 27, 2013 Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). F2 · ownership.nature: The Reporting Person is the trustee of The Barker/Loring Trust and has voting and dispositive power with respect to these shares. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 20:01 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Disposition to issuerCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-027089 · ownership.xml · nonDerivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration"). Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001411690-24-000034 · wk-form4_1718914965.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 29, 2024 Filed May 31, 2024 18:30 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0000950170-24-067531 · ownership.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2025 Annual Meeting of Stockholders or May 29, 2025. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:14 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001411690-23-000051 · wf-form4_168694646055716.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 25, 2023 Filed May 26, 2023 17:02 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001209191-23-032597 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2033-05-25 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2024 Stockholder Annual Meeting or May 25, 2024. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 19:00 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001209191-22-041844 · doc4.xml · derivative · entry 3 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2029-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Option granted under the Singular Genomics Systems, Inc. 2016 Stock Plan. The option shares are fully vested and may be exercised at any time. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 19:00 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | Exercise / conversionCommon Stock | 60,000 | $0.63 | $37,800.00 |
DisclosureSEC source: 0001209191-22-041844 · doc4.xml · nonDerivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:51 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001411690-22-000016 · wf-form4_165757265259092.xml · derivative · entry 2 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares vested in equal monthly installments over a one year period such that the option became fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| July 07, 2022 Filed Jul 11, 2022 20:51 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | Exercise / conversionCommon Stock | 44,470 | $0.51 | $22,679.70 |
DisclosureSEC source: 0001411690-22-000016 · wf-form4_165757265259092.xml · nonDerivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:29 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 164,422 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036320 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,422 Underlying: Common Stock · 164,422 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| May 26, 2022 Filed May 31, 2022 21:00 UTC | Singular Genomics Systems, Inc. OMIC · Entity 82741 | GrantStock Option (Right to Buy) · Derivative | 46,250 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001209191-22-033015 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 46,250 shares Expires 2032-05-26 F1 · derivative.exercise_date: The option shares vest and become exercisable upon the earlier of the 2023 Stockholder Annual Meeting or May 26, 2023. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 10,000 | $1.60 | $16,000.00 |
DisclosureSEC source: 0001209191-22-030026 · doc4.xml · nonDerivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,894 Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:49 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 40,751 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001209191-21-052603 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,751 Underlying: Common Stock · 40,751 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following June 10, 2021, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 23:19 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 7,528 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-21-040409 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 Underlying: Common Stock · 7,528 shares Expires 2031-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 3, 2020 00:26 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040750 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 21:33 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 21,911 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001209191-19-035898 · doc4.xml · derivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,911 Underlying: Common Stock · 21,911 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 6, 2020, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:42 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 10,516 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053847 · doc4.xml · derivative · entry 3 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,516 Underlying: Common Stock · 10,516 shares Expires 2028-09-30 F3 · derivative.exercise_date: The shares subject to the option shall vest monthly over 36 months beginning on the one-month anniversary of October 1, 2018 (the "Vesting Commencement Date") such that the option shall be fully vested and exercisable on the three year anniversary of the Vesting Commencement Date. Read SEC document |
| August 21, 2018 Filed Oct 3, 2018 20:42 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 3,894 | $6.47 Strike: $6.47 | $25,194.18 |
DisclosureSEC source: 0001209191-18-053847 · doc4.xml · derivative · entry 2 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,894 Underlying: Common Stock · 3,894 shares Expires 2023-08-21 F1 · price: The price reported in column 4 is a weighted average price. These units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, were purchased in multiple transactions at prices ranging from $6.37 to $6.4971, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units purchased at each separate price within the ranges set forth herein. Units purchased at a price of $6.47 per unit, . F2 · derivative.exercise_date: September 21, 2018 or such earlier date as Roth Capital Partners LLC, as representative of the underwriters in the Company's Initial Public Offering, shall determine. Read SEC document |
| August 21, 2018 Filed Oct 3, 2018 20:42 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 3,894 | $6.47 | $25,194.18 |
DisclosureSEC source: 0001209191-18-053847 · doc4.xml · nonDerivative · entry 1 BARKER DAVID L · CIK 0001189124 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,894 F1 · price: The price reported in column 4 is a weighted average price. These units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock, were purchased in multiple transactions at prices ranging from $6.37 to $6.4971, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of units purchased at each separate price within the ranges set forth herein. Units purchased at a price of $6.47 per unit, . Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.